117 related articles for article (PubMed ID: 2868473)
1. Neuroleptic withdrawal in chronic schizophrenia: CT and endocrine variables relating to psychopathology.
Naber D; Albus M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Wissmann J; Ackenheil M
Psychiatry Res; 1985 Nov; 16(3):207-19. PubMed ID: 2868473
[TBL] [Abstract][Full Text] [Related]
2. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables].
Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J
Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983
[TBL] [Abstract][Full Text] [Related]
3. Tardive dyskinesia: relation to computer-tomographic, endocrine, and psychopathological variables.
Albus M; Naber D; Müller-Spahn F; Douillet P; Reinertshofer T; Ackenheil M
Biol Psychiatry; 1985 Oct; 20(10):1082-9. PubMed ID: 2864087
[TBL] [Abstract][Full Text] [Related]
4. beta-Endorphin, cortisol, and prolactin in serum of schizophrenic patients during long-term neuroleptic treatment and after withdrawal: relationships to psychopathology.
Naber D; Albus M; Muller F; Burke H; Welter D; Ackenheil M; Hippius H
Psychopharmacol Bull; 1982 Oct; 18(4):224-6. PubMed ID: 6130563
[No Abstract] [Full Text] [Related]
5. Neuroendocrinological and biochemical effects of chronic neuroleptic treatment.
Hippius H; Ackenheil M; Müller-Spahn F
Adv Biochem Psychopharmacol; 1985; 40():9-13. PubMed ID: 2862769
[No Abstract] [Full Text] [Related]
6. No correlation between neuroleptic-induced increase of beta-endorphin serum level and therapeutic efficacy in schizophrenia.
Naber D; Nedopil N; Eben E
Br J Psychiatry; 1984 Jun; 144():651-3. PubMed ID: 6146374
[TBL] [Abstract][Full Text] [Related]
7. Prolactin shifts after neuroleptic withdrawal.
Green AI; Faraone SV; Brown WA
Psychiatry Res; 1990 Jun; 32(3):213-9. PubMed ID: 1975101
[TBL] [Abstract][Full Text] [Related]
8. Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extrapyramidal symptoms.
Naber D; Finkbeiner C; Fischer B; Zander KJ; Ackenheil M
Neuropsychobiology; 1980; 6(4):181-9. PubMed ID: 6104798
[TBL] [Abstract][Full Text] [Related]
9. Naloxone treatment for five days ineffective in schizophrenia. Neuroendocrine actions of the opiate antagonist.
Naber D; Münch U; Wissmann J; Grosse R; Ritt R; Welter D
Acta Psychiatr Scand; 1983 Apr; 67(4):265-71. PubMed ID: 6305111
[No Abstract] [Full Text] [Related]
10. Lateral ventricular enlargement and clinical response in schizophrenia.
Smith RC; Baumgartner R; Ravichandran GK; Mauldin M; Burd A; Vroulis G; Gordon J; Calderon M
Psychiatry Res; 1985 Mar; 14(3):241-53. PubMed ID: 3858896
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.
Emrich HM; Höllt V; Bergmann M; Kissling W; Schmid W; Zerssen DV; Herz A
Adv Biochem Psychopharmacol; 1980; 22():489-502. PubMed ID: 6104902
[No Abstract] [Full Text] [Related]
12. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
Faraone SV; Brown WA; Laughren TP
J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
[TBL] [Abstract][Full Text] [Related]
13. Atrophic and static (neurodevelopmental) schizophrenic psychoses: premorbid functioning, symptoms and neuroleptic response.
Garver DL; Nair TR; Christensen JD; Holcomb J; Ramberg J; Kingsbury S
Neuropsychopharmacology; 1999 Jul; 21(1):82-92. PubMed ID: 10379522
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome.
Tandon R; Mazzara C; DeQuardo J; Craig KA; Meador-Woodruff JH; Goldman R; Greden JF
Biol Psychiatry; 1991 May; 29(10):953-64. PubMed ID: 1676605
[TBL] [Abstract][Full Text] [Related]
15. Lateral ventricular size, psychopathology, and medication response in the psychoses.
Luchins DJ; Lewine RR; Meltzer HY
Biol Psychiatry; 1984 Jan; 19(1):29-44. PubMed ID: 6142730
[TBL] [Abstract][Full Text] [Related]
16. (Des-tyrosine1)-gamma-endorphin in schizophrenia: clinical, biochemical, and hormonal aspects.
Verhoeven WM; Westenberg HG; Gerritsen TW; van Praag HM; Thijssen JH; Schwarz F; van Ree JM; de Wied D
Psychiatry Res; 1981 Dec; 5(3):293-309. PubMed ID: 7034028
[TBL] [Abstract][Full Text] [Related]
17. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
Kuhs H; Folkerts H
Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
[TBL] [Abstract][Full Text] [Related]
18. Response to drugs in schizophrenia: the influence of family history, obstetric complications and ventricular enlargement.
Nimgaonkar VL; Wessely S; Tune LE; Murray RM
Psychol Med; 1988 Aug; 18(3):583-92. PubMed ID: 2903512
[TBL] [Abstract][Full Text] [Related]
19. Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patients.
Pickar D; Davis GC; Schulz SC; Extein I; Wagner R; Naber D; Gold PW; van Kammen DP; Goodwin FK; Wyatt RJ; Li CH; Bunney WE
Am J Psychiatry; 1981 Feb; 138(2):160-6. PubMed ID: 6257125
[TBL] [Abstract][Full Text] [Related]
20. Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients.
Wilms G; Van Ongeval C; Baert AL; Claus A; Bollen J; De Cuyper H; Eneman M; Malfroid M; Peuskens J; Heylen S
Acta Psychiatr Scand; 1992 Apr; 85(4):306-12. PubMed ID: 1375802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
